The presence of apolipoprotein (apo) B in liver and intestine from a patient with abetalipoproteinemia was evaluated by immunohistochemistry with a polyclonal and six monoclonal antibodies to different apo B-48 and B-100 epitopes. In normal liver, apo B was present inside and outside hepatocytes. The patients liver exhibited staining in the cytoplasm with the polyclonal and three monoclonal antibodies. By immunoelectronmicroscopy, apo B was found to be present in the smooth endoplasmatic reticulum and the Golgi complex. Normal intestinal epithelium was labeled with polyclonal and all monoclonal antibodies, including those specific for apo B-100. The patients epithelium stained with polyclonal and six monoclonals, and apo B was present in the Golgi complex.
Introduction
Apolipoprotein (apo)1 B is an obligatory protein constituent of chylomicrons, very low density lipoproteins (VLDL: d < 1.006 g/ml), and low density lipoproteins (LDL: d 1.006-1.063 g/ml). It is present in plasma primarily in two forms, which are designated apo B-48 and apo B-100 according to a centile nomenclature system (1) . Apo B is the most poorly characterized apolipoprotein, due to its chemical and physical properties. In man, apo B-100 is synthesized in the liver and is found in VLDL and LDL, whereas apo B-48 is synthesized in the intestine and is a constituent of chylomicrons (2) . Apo B-48 is produced in the rat both in the liver and the intestine (3, 4) . Minor quantities of apo B-100 have been isolated from human thoracic duct lymph (1), but not (4) , or in only trace amounts, from rat mesenteric duct lymph (5) . Apo B-48 and apo B-100 are closely related structurally (6, 7) , but their synthesis is possibly under different genetic control (6) . Previous studies using monoclonal antibodies against human LDL showed a possible sequence homology between the two protein moieties (7) .
Classical abetalipoproteinemia is a very rare autosomal recessive disorder, which was first described in 1950 by Bassen and Kornzweig (8) . Its hallmark is the absence of apo B-and apo B-containing lipoproteins from plasma (9, 10) . Heterozygotes are phenotypically normal. Other apo B deficiency syndromes include familial hypobetalipoproteinemia, which is transmitted as an autosomal dominant trait, where heterozygotes have LDL cholesterol levels -50% of normal and homozygotes are clinically and biochemically similar to patients with recessive abetalipoproteinemia (10, 11) ; normotriglyceridemic abetalipoproteinemia, in which apo B-100 is absent from plasma (12) (13) (14) ; and familial hypobetalipoproteinemia with chylomicronemia, which is characterized by very low levels of LDL and fasting chylomicronemia (15) . The molecular basis of the various apo B deficiency syndromes has not yet been identified. In recessive abetalipoproteinemia defects in apo B synthesis, intracellular assembly, secretion ofapo B-containing lipoproteins, and rapid catabolism of apo B have been hypothesized (12, 16) . Clinical symptoms of this disorder include malabsorption of fat as a direct result ofdefective chylomicron transport; neuromuscular manifestations, such as spinocerebellar degeneration and peripheral neuropathy; retinitis pigmentosa; and acanthocytosis of erythrocytes (16) . Intestinal biopsies invariably show accumulation of fat in the enterocytes (10) . Using rabbit antiserum to human LDL in immunohistochemistry, apo B could not be demonstrated in intestinal epithelial cells from two cases with abetalipoproteinemia (17) . Hepatic steatosis is often present, but usually without clinical manifestation of liver disease.
In this report a patient with recessive abetalipoproteinemia is described. We had the opportunity to use a series of monoclonal antibodies to various epitopes on apo B (7) in an immunohistochemical study on the expression of apo B in normal liver and intestine and to document the deficiency in this patient at the tissue level. Since immunohistochemical presence does not prove local synthesis, immunoelectronmicroscopy was performed with special attention to the endoplasmatic reticulum, the Golgi complex, and secretion granules.
Methods
Case report A 29-yr-old female was referred for further evaluation of abetalipoproteinemia, which was diagnosed elsewhere at the age of 25. She was the only child of Dutch consanguinous parents. Her parents and her two half-brothers were healthy. Her youth was uneventful, although she showed a notable intolerance for fatty foods. Because of her clumsiness, the patient was seen by a neurologist when she was 14. Slight pes cavus, absence oftendon reflexes, and an intention tremor were observed, and a tentative diagnosis of a heredo familial spinocerebellar degenerative condition was made. Loss ofvisual acuity and retinitis pigmentosa were observed when she was 25 yr ofage. No beta or prebetalipoproteins were seen on agarose gel electrophoresis of plasma. A blood smear showed that 60-70% of the erythrocytes were acanthocytes. The diagnosis of abetalipoproteinemia was made. She was treated with megadoses oforally administered vitamin E (5 g daily) in an attempt to delay the progression of the neurological and retinal lesions (18, 19) . During the 1st year on vitamin E treatment, her neurological condition stabilized, but afterwards she noted progression and further decrease of vision.
At referral she appeared well nourished, weighing 46 kg and standing 1.53-m tall. Her skin was scaly, probably as a result of essential fatty acid deficiency (20 (Fig. 1) .
Plasma apo B was assayed by kinetic immunoturbidimetry as previously described for albumin (22) 
Anti-apo B antibodies
Polyclonal rabbit anti-human apo B antiserum was prepared by immunizing a rabbit with human LDL, and the antiserum was isolated in a narrow density range (d 1.035-1.045 g/ml). The antiserum did not show cross-reactivity with apo A-I, apo A-II, apo C-II, apo C-Ill, or apo E as evaluated by double immunodiffusion (Ouchterlony Technique) using serial dilutions of both antiserum and antigen.
Six monoclonal antibodies against human LDL, which were obtained from hybridomas, were the product of a cell fusion between cells of the plasmacytoma cell line SP 2-0 (23) and isolated spleen cells from BALB/c mice that were previously immunized with human LDL Details of the procedure and characterization of the antibodies have been described elsewhere (7, 24) . Based on co-titration experiments with these monoclonal antibodies, a hypothetical map of epitopes on apo B-100 and apo B-48 has been proposed (7), which is summarized in Fig. 2 . 
Immunohistochemistry
Part ofthe biopsies were fixed in 4% formalin and embedded in paraffin. 14 . , , F 17 spaces are stained more intensely (arrow) than the sinusoids (b) Liver of a patient with abetalipoproteinemia. The sinusoids are empty (arrow) and the cytoplasm of hepatocytes is stained faintly with exclusion of nuclei and fat vacuoles (*).
Tissue Apolipoprotein B Epitopes in Abetalipoproteinemia 1399 4 'ii To assess the specificity of the polyclonal antiserum, this was absorbed with human LDL, which contains exclusively apo B-100, prepared, and washed by repeated ultracentrifugation. After absorption there was no labeling of tissue sections in immunofluorescence.
Immunoelectronmicroscopy
The patients liver and intestinal biopsies, one control human liver, and two control human duodenal biopsies were immediately immersed in 0.5% glutaraldehyde in 0.1 M phosphate buffer at room temperature for 60 min. Small tissue blocks were stored at 4VC in a solution of 2% formaldehyde and 1 M sucrose in 0.1 M phosphate buffer until processing. The duodenal biopsy of the patient was rinsed after fixation in 0.1 M phosphate buffer and transferred to 10% gelatin in phosphate buffer at 370C. The gelatin was allowed to solidify at 00C before being fixed with 2% formaldehyde for 15 min.
Ultrathin cryosections were obtained according to Tokuyasu and Singer (25) . About 100-nm cryosections were incubated with either rabbit anti-apo B antiserum or monoclonal anti-apo B antibody. The antibody Liver sections of the patient revealed, using the polyclonal antiserum, a faint staining of the cytoplasm of the hepatocytes. The staining was considered specific, since it was not present when the antibody was used after absorption with normal LDL; in addition, liver sections were not labeled when incubated with nonimmune rabbit serum. Blood vessels and sinusoidal spaces were negative.
The various monoclonal reagents labeled in different patterns. No reaction was seen using monoclonal antibodies 2D8, 3F5, and 5E1 1. A faint to very faint staining of the cytoplasm ofthe hepatocytes in a fine granular pattern was observed using antibodies lDl, 4G3, and 3A8. Apart from the labeling of antibody lDl, which was observed only in the second biopsy, no difference in labeling between the two biopsies was noticed. Blood vessels and sinusoidal spaces were negative using all monoclonal reagents. Fg 4 illustrates the labeling of a liver section from a normal control and from the abetalipoproteinemic patient using monoclonal antibody 3A8.
INTESTINE. In sections of control jejunum, either the polyclonal anti-apo B antiserum or one ofthe monoclonal antibodies gave a granular staining of the enterocytes, dspeciAlly at the luminal side. The intensity of staining was similar at the top of the villi and in the crypts. Identical labeling occurred, using the various monoclonal reagents.
The staining of the patient's jejunal biopsy using the polyclonal antiserum did not differ quantitatively from the normal picture, except for a more pronounced labeling of the crypt ep- ithelium. In addition, the enterocytes were stained by all monoclonal reagents. The intensity of staining was as normal using monoclonal antibodies IDi, 2D8, 3A8, and 5E1 1, but was rather faint using 3F5 and 4G3. None of the reagents labeled blood vessels. Both jejunal biopsies ofthe patient showed similar staining. The staining of a jejunal section from a normal control and from the abetalipoproteinemic patient using monoclonal antibody 3A8 is illustrated in Fig. 5 .
The results of the labeling of liver and jejunal sections from the patient with abetalipoproteinemia with the panel of six monoclonal antibodies are summarized in Table I .
None of the controls mentioned in the Methods section contained gold labeling. The labeling after incubation of the tissue specimens with the monoclonal antibodies were weak in comparison to the polyclonal. Immunoelectronmicroscopic localization of apo B in the liver of the patient demonstrated gold particles in the cisternae of the Golgi complex and developing secreting granules (Fig. 6 a) , and also in the smooth endoplasmatic reticulum (Fig. 6 b) . In the patient's intestine electronmicroscopy, gold particles in the Golgi complex (Fig. 7) , but also in some of the intercellular spaces, were revealed.
Discussion
In a patient with recessive abetalipoproteinemia we were able to document expression of apo B epitopes in liver and jejunum, while apo B was not detectable in her plasma. normal liver and intestine is compatible with the literature (17, 30) . In man, apo B was present in enterocytes, especially at the luminal side of the cell (17), using a monospecific anti-human LDL antiserum and in homogenates of duodeno-jejunal absorptive cells (30) . In the rat, apo B was demonstrated in the enterocytes (31, 32) and in liver tissue, in both cases with a fine granular pattern in the cytoplasm of hepatocytes and along sinusoidal spaces, using polyclonal rabbit anti-rat LDL antisera (32) similar to that used in our present experiment and in our earlier reported (33) results in man.
Using monoclonal antibodies to human apo B, a map of epitopes on apo B-100 and apo B-48 was proposed previously (7) . It is commonly assumed that, in human plasma, apo B-100 is of hepatic origin, and that apo B-48 is of intestinal origin (2) . Since the two available monoclonal antibodies to epitopes on apo B-48 also react with apo B-100, the similar staining patterns using the different antibodies do not allow any conclusions with respect to human hepatic apo B-48 synthesis.
Although apo B-48 and apo B-100 were present in human thoracic duct lymph (1), the issue of intestinal apo B-100 synthesis has not yet been settled, since the presence of apo B-100 in thoracic duct lymph can be the consequence of drainage of hepatic lymph into this system. The present results, showing labeling of intestinal epithelium with monoclonal antibodies to epitopes on apo B-100, and not reacting with epitopes on apo B-48, suggest that normal jejunum can synthesize both apo B-48 and apo B-100.
However, apo B-48 is undoubtedly the most abundant product of intestinal apo B secretion (1) . The genetic basis of apo B heterogeneity remains unknown. The present results are also compatible with the proposed concept (7) that apo B-48 and apo B-100 are products of the same gene and that apo B-48 is a cleavage product of apo B-100. The protein subspecies ultimately secreted in the circulation or lymph could be the result of different posttranslational processing in intestine and hepatocytes.
The clinical disorder of our patient is clearly compatible with recessive abetalipoproteinemia (10, 16) . Using a polyclonal rabbit anti-human apo B antiserum, apo B was undetectable in plasma, in endothelium of blood vessels, and along sinusoidal spaces. In contrast, the hepatocytes showed a faint but specific staining and the enterocytes labeled normally using this polyclonal antiserum. Furthermore, the patient's intestinal epithelium labeled with all and the hepatocytes labeled with three monoclonal antibodies. The different labeling patterns in liver and jejunum using monoclonal antibodies 2D8, 3F5, and 5E 1I are not readily explained, but could be the result of defective modification (such as glycosylation) or defective synthesis ofthe apo B-100 protein chain in the patient's liver. It could also be the result of a lack in sensitivity of the applied immunohistochemical technique in liver sections. The immunohistochemical data as described in this paper do not provide evidence ofwhether or not apo B is present in the synthetic apparatus ofthe patient's liver and gut cells, or whether it is localized in other cellular compartments. However, the highly sensitive immunoelectronmicroscopic technique used (34) shows specific staining of apo B and localization of the gold particles in the smooth endoplasmatic reticulum, the Golgi complex, and secretory granules. In normal jejunal absorptive cells (35) and rat liver cells (36) , ultrastructural immunolocalization has been performed before.
In view of the localization described by us, the conclusion that apo B, or at least part of the apo B molecule recognized by the antibodies, is synthesized in both the liver and gut of the abetalipoproteinemic patient seems inescapable.
The present results are in contrast with the report of Glickman (17) in which the absence of apo B immunoreactivity in enterocytes of two abetalipoproteinemic patients was documented. Based on these results a genetic defect in the synthesis of the apo B protein has been proposed (16, 17) . Other theories include disturbances in posttranslational modifications of the apo B protein structure, such as defects in polymerization ofthe subunits or glycosylation and defects in regulator genes (12) . Besides, a defect in secretion of apo B from the cell has been proposed (16) . Our results suggest a defect in secretion of apo B or appropriate association with lipids both in liver and intestine. Therefore, it cannot be excluded that recessive abetalipoproteinemia is a heterogeneous disorder and that this patient has a disorder phenotypically identical with recessive abetalipoproteinemia, but with a genetic defect different from other patients described. Very recently, the gene of human apo B-I00 has been cloned. By molecular genetic techniques, messenger RNA of apo B-100 has been found in hepatocytes of another abetalipoproteinemic patient (37) , which is concordant with the present immunohistochemical study.
